Non-Insulin Diabetes Medications Summary

Transcription

1 Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential for hypoglycemia. 1.25, 2.5, times/day Take to avoid hypoglycemia MICRONIZED GLYBURIDE* (Glynase Prestabs) 1.5, 3, times/day With meals GLIPIZIDE* (Glucotrol) 5, times/day 30 minutes pre-meal GLIPIZIDE EXTENDED RELEASE* (Glucotrol XL) 2.5, 5, times/day With meals 5 20 GLIMEPIRIDE* (Amaryl) 1, 2, 4 1 time/day With meals Meglitinides* REPAGLINIDE* (Prandin) production. Side effects: Potential for hypoglycemia 0.5, 1, 2, times/day, 0 30 min pre meals Skip meal, skip dose Add meal, add dose to total of 4 doses/day D-Phenylalanine Derivative* NATEGLINIDE* (Starlix) production. Side effects: Potential for hypoglycemia 60, times/day, 0 30 min pre meals Skip meal, skip dose Rev 5.14

2 GLUCOSE SUPPRESSORS Biguanides METFORMIN (Glucophage) Action: Decreases hepatic glucose production, and improves glucose transport. Side effects: Gas, diarrhea, lactic acidosis. To decrease lactic acidosis risk, avoid in: - Liver disease, alcohol abuse/bingeing- If creatinine 1.4 mg/dl in women; 1.5 mg/dl in men - IV contrast - Recurrent CHF - Severe infection, acute MI - 80 years age unless creatinine clearance is normal. Hold for IV contrast dye, surgery or severe vomiting or diarrhea. Repeat creatinine in 48 hrs; if OK, restart metformin. 500, 850, times/day Take to avoid stomach upset : Take with food to decrease gas, diarrhea. METFORMIN EXTENDED RELEASE (Glucophage XR) 500, times/day METFORMIN EXTENDED RELEASE (Fortamet) 500, time/day METFORMIN EXTENDED RELEASE (Glumetza) 500, time/day METFORMIN ORAL SOLUTION (Riomet) 500mg (5ml) 2 3 times/day

3 MED GROUP DESCRIPTOR INSULIN SENSITIZERS Thiazolidinediones ROSIGLITAZONE (Avandia) Note: The FDA has now determined that in addition to describing the cardiovascular risks (such as heart attack or stroke ) of rosiglitazone and rosiglitazone-containing medicines the drug labels must be revised to state that use of the drug is limited to: Patients already being treated with these medicines Patients whose blood glucose cannot be controlled with other antidiabetic medicines and who, after consulting with their healthcare professional, do not wish to use pioglitazone-containing medicines (Actos, Actoplus Met, Actoplus Met XR, Duetact or Oseni). Action (both): Improves glucose transport, and decreases hepatic glucose production. May have beneficial effect on endothelium. Side effects (both): Weight gain, fluid retention, osteopenia, increase in CHF in those at risk. Liver disease check LFTs at baseline then periodically. (both): May cause resumption of ovulation in perimenopausal women. Take same time daily May require up to 2 weeks to see an effect. Maximum recommended dosage of pioglitazone 15mg/day with drugs that are strong inhibiters of CYP2C8, such as gemfibrozil. 2, 4, times/day Same time daily 4 8 PIOGLITAZONE (Actos) 15, 30, 45 1 time/day Same time daily DPP-4 INHIBITORS SITAGLIPTIN (Januvia) SAXAGLIPTIN (Onglyza) LINAGLIPTIN (Tradjenta) ALOGLIPTIN (Nesina) Action: Slows the inactivation of incretin hormones, resulting in increased insulin synthesis and decreased glucagon levels in a glucose-dependent manner. Side effects: URI, stuffy nose, sore throat, occasional diarrhea and stomach discomfort. (UTI with Onglyza) : Decrease dose for renal disease with sitagliptin, saxagliptin and alogliptin. No dosage adjustment is needed with linagliptin Watch for interactions with drugs that induce P-glycoprotein or CYP450 3A4 enzymes (with linagliptin), or inhibit CYP 3A4 enzymes (with saxagliptin) 25, 50, , , 12.5, time/day unrelated to food. Same time daily 1 time/day unrelated to food. Same time daily 1 time/day unrelated to food. Same time daily 1 time/day unrelated to food. Same time daily

4 STARCH BLOCKERS Alpha-Glucosidase Inhibitors MIGLITOL (Glyset) ACARBOSE (Precose) Action: Delays absorption and breakdown of carbohydrates from intestines. Side effects: Gas, diarrhea. Elevation of LFTs with acarbose in doses >50mg tid, and wt < 132 lbs. : Use glucose to treat hypoglycemia when used in combination therapy Dose low and increase slowly to decrease flatulence 25, 50, times/day with first bite of meal 25, 50, times/day with first bite of meal GLUCOSE EXCRETORS SGLT2 Inhibitors CANAGLIFLOZIN (Invokana) DAPAGLIFLOZIN (Farxiga) EMPAGLIFLOZIN (Jardiance) Action: Lowers blood glucose by reducing renal glucose reabsorption and increasing urinary glucose excretion. Side effects: UTI, increased urination, genital fungal infection, hypoglycemia when used with insulin or insulin secretagogues, dehydration, thirst, hypotension, increased LDL cholesterol, weight loss, hyperkalemia (in canagliflozin); possible risk of bladder cancer (in dapagliflozin) : Dose of canagliflozin may be increased to 300 mg/day if egfr 60 and further glycemic control needed. Avoid use in patients with egfr <45. Contraindicated in patients with severe renal impairment, ESRD or on dialysis. Do not use if patients have severe renal impairment (for canagliflozin, egfr less than 30 ml/min during dialysis; for dapagliflozin, egfr < 60 ml/min) time/day taken before first meal of the day time/day taken in the morning, with or without food Once daily 10 or 25

5 BILE ACID SEQUESTRANTS COLESEVELAM (Welchol) Action: Bile acid sequestrant that reduces LDL cholesterol and improves glycemic control. Side effects: constipation, nausea, diarrhea, gas, heartburn, headache. May interact with glyburide, levothyroxine and contraceptives. 625 mg tablet 1.875g, 3.75g powder packet 6 tablets (or 3.75g powder packet) daily or 3 tablets (or 1.875g powder packet) twice daily with a meal and liquid

6 MED GROUP DESCRIPTOR DOPAMINE AGONIST BROMOCRIPTINE MESYLATE* (Cycloset) Action: Unknown; lowers glucose without increasing insulin. Reduces the risk of MI and stroke. 0.8mg 1 time/day with food within 2 hrs of waking Side effects: hypotension, orthostatic changes, fainting, drowsiness, may worsen psychotic disorders, hypoglycemia, nausea, fatigue, severe dizziness. FIXED COMBINATIONS GLYBURIDE and METFORMIN* (Glucovance) GLIPIZIDE and METFORMIN* (Metaglip) production and decreases hepatic glucose production. sulfonylureas and biguanides mg/ /500 5 / / /500 5 / times/day 1 2 times/day ROSIGLITAZONE and METFORMIN (Avandamet ) Action: Improves glucose transport, and decreases hepatic glucose production. thiazolidinediones and biguanides. 1 /500 2 /500 4 /500 2 / / times/day PIOGLITAZONE and METFORMIN (Actoplus Met) Action: Improves glucose transport, and decreases hepatic glucose production. thiazolidinediones and biguanides. 15 / / times/day / REPAGLINIDE and METFORMIN (Prandimet) production and decreases hepatic glucose production. meglitinides and biguanides 1 /500 2 / times/day 15 minutes premeal Skip meal, skip dose ; Max dose 10 /2500 CANAGLIFLOZIN and METFORMIN (Invokamet) Action: Lowers blood glucose by reducing renal glucose reabsorption and increasing urinary glucose excretion. Decreased hepatic glucose production Side effects: See above information for canagliflozin and Biguanides 50/500 50/ / / times/day with breakfast and supper 50 or 150/500 or 1000 See note under thiazolidinediones regarding limitations on use

7 ROSIGLITAZONE and GLIMEPIRIDE* (Avandaryl ) Action: Improves glucose transport, decreases hepatic glucose production and stimulates β-cell insulin production. thiazolidinediones and sulfonylureas. 4 /1 4 /2 4 /4 1 time/day with first meal PIOGLITAZONE and GLIMEPRIDE* (Duetact) ALOGLIPTIN and PIOGLITAZONE (Oseni) SITAGLIPTIN and METFORMIN (Janumet) SITAGLIPTIN and METFORMIN ER (Janumet XR) SAXAGLIPTIN and METFORMIN ER (Kombiglyze XR) Action: Improves insulin action in adipose tissue, liver, and skeletal muscle; May have beneficial effect on vascular cells and β cells, stimulates β-cell insulin production. pioglitazone and glimepiride. See above for alogliptin See above for pioglitazone Action: Slows the inactivation of incretin hormones, resulting in increased insulin synthesis and decreased glucagon levels in a glucose dependent manner. Decreases hepatic glucose production, and improves glucose transport. sitagliptin, saxagliptin, linagliptin, alogliptin and metformin. Reduce Kombiglyze to 2.5 mg/1000 if also taking strong CYP3A4/5 inhibitors, such as ketoconazole. 15, 30, 45 1 time/day before first meal 12.5/ / /45 50/500 50/1000 5/500 5 / /1000 Start at 15 /day; Increase every 4 to 8 weeks or more, as needed, to 30 /day, and then to 45 /day 1 time/day 2 times/day, taken with food 1 time/day with evening meal 1 time/day with evening meal LINAGLIPTIN and METFORMIN (Jentadueto) Consider alternative treatment to Jentadueto if CYP3A4 or P-gp inducers are taken. 2.5/ / / times/day, taken with food ALOGLIPTIN and METFORMIN (Kazano) 12.5/ / times/day, taken with food SITAGLIPTIN and SIMVASTATIN (Juvisync) Action: See above for sitagliptin. Simvastatin is an HMG-CoA reductase inhibitor (statin) that inhibits the enzyme that catalyzes the conversion HMG-CoA to mevalonate (an early and ratelimiting step in cholesterol biosynthesis), thereby decreasing total cholesterol, LDL cholesterol, Apo B and triglycerides. sitagliptin. Side effects for simvastatin may include URI, headache, abdominal pain, myopathy and rhabdomyolysis. See note under Thiazolidinediones regarding limitations on use 100/10 100/20 100/40 1 time/day in the evening. amount of simvastatin required to achieve lipid goals. Start at 100/40 per day.

8 Injectables GLP-1 Receptor Agonists* EXENATIDE (Byetta) LIRAGLUTIDE (Victoza) EXENATIDE EXTENDED-RELEASE (Bydureon) TANZEUM (Albiglutide) Amylin mimetic* PRAMLINTIDE (Symlin) Action: Increases the level of incretin hormones, resulting in enhanced insulin secretion and reduced glucagon secretion in a glucosedependent manner. Side Effects: Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) Pancreatitis, hypoglycemia can occur when used in combination with insulin or secretagogues. Common side effects include nausea vomiting or diarrhea, reactions at the injection site, cough, back pain and cold or flu symptoms Action: Exact mechanism unknown. Decreases postprandial glucose suppresses glucagon secretion, slows gastric emptying similar to GLP-1 agonists. Side Effects: Nausea, anorexia, vomiting. 5,10 mcg/dose (multi-dose prefilled pen) 0.6, 1.2, 1.8 mg/dose (multi-dose prefilled pen) 2 mg by subcutaneous injection 30,50 mg/single-dose pen Type 2 60 mcg to 120 mcg (multidose prefilled pen) Type 1 15 mcg to 60 mcg (multidose prefilled pen) 2 times/day 0-60 min pre-meals (6+ hours apart) mcg/day 1 time/day mg/day (initiate at 0.6 mg/day) 1 time every 7 days (once per week) 1 time every 7 days (once per week) Immediately prior to meals containing 250 calories or 30 grams of carbohydrates 2 mg/week 30 to 50 mg/week mcg/day mcg/day